WinstonWınston
Enovis Corporation logo

Enovis Corporation

ENOV
26
Medical - Devices · Healthcare
Also trades as: 0I1B.L
Price
$24.34
-0.26 (-1.06%)
Market Cap
$1.40B
Winston Score
26
Winston is worried
Below-average fundamentals — multiple weak pillars.
Data as of Aug 12, 2026 · filings through Jul 3, 2026

Share count rising — dilution

+11.0% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 51.1M (2021) → 56.8M (2025)

Enovis Corporation makes medical devices used to help people recover from injuries and surgeries. Its main products include braces, joint reconstruction implants, and physical therapy equipment sold to hospitals, orthopedic surgeons, and rehabilitation clinics. The company focuses on the orthopedics and reconstructive care market, and it expanded significantly after acquiring Colfax's medical segment and later buying Lima Corporate, a European joint implant maker.

Enovis earns money by selling its devices and implants directly to healthcare providers, primarily through a direct sales force. It operates across North America, Europe, and other international markets, generating roughly $2 billion in annual revenue. The company's competitive position relies on its broad product portfolio and surgeon relationships, but its thin operating margin and low return on invested capital suggest it is still working to absorb recent acquisitions efficiently. The key challenge ahead is improving profitability while integrating those acquisitions in a market with strong competition from larger rivals like Zimmer Biomet and Stryker.

Winston Score History

Politician Trades

3 trades / 12mo

1 Congressional buy and 2 sells on ENOV in the last 12 months.

Unlock the full Smart Money Map — every trade plotted on the price chart with politicians, amounts and returns since each trade. Founder's Deal is $57/mo locked for life.

Unlock politician trades

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+3.2% YoY

YoY Growth Rate

Slow revenue growth

EPS Growth

+96.9% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$120M/ year

Rising (+32% vs prior year)

5.4% of revenue

Below sector average (18%)

R&D investment increasing — building for the future

Insider Activity

1.7%ownership

Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

$13M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Company generates more cash than it spends — no dilution risk from fundraising

Growth context

Enovis Corporation is growing revenue at 3% year-over-year. The Winston Score measures business quality today — these growth metrics show what could matter tomorrow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
61.6%
Premium pricing power — 61.6% gross margin
Operating Margin
3.0%
Thin — 3.0% operating margin
ROCE
0.6%
Weak — 0.6% return on capital

ROIC between 0% and 5%. They earn a few cents back per dollar invested in the business.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
+4.9%
Slow sales growth (+4.9% YoY)
EPS YoY
N/A
Data not available
EPS Consistency
4/8 quarters
Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
N/A
Data not available
FCF Margin
2.8%
Thin free cash flow (2.8%)

FCF margin between 0% and 10%. Some cash from sales, but not a lot.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
0.87
Moderate — manageable debt (0.87)
Interest Cover
1.71x
Dangerous — barely covers interest (1.7x)

Interest coverage between 1 and 3. Profits cover interest, but with little room to spare.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)
N/M
Negative earnings — P/E not meaningful
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial